Add Vivus (VVUS +4.1%) to the list of companies showing a gain on speculation that demand for obesity drugs will take off following Orexigen's (OREX +52%) restart on development of Contrave. The momentum buying looks to be led by loose talk the FDA will ease obesity drug standards, which doesn't quite fall in line with analysts and the agency itself (I, II).
Add Vivus (VVUS +4.1%) to the list of companies showing a gain on speculation that demand for...
From other sites
at CNBC.com (Dec 2, 2014)
at CNBC.com (Dec 1, 2014)
at CNBC.com (Oct 27, 2014)
at CNBC.com (Sep 18, 2014)
at CNBC.com (Sep 11, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs